Paul Matteis
Stock Analyst at Stifel
(2.93)
# 2,629
Out of 5,182 analysts
131
Total ratings
43.18%
Success rate
0.17%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $20.98 | +42.99% | 1 | Apr 17, 2026 | |
| IMUX Immunic | Initiates: Buy | $25 | $9.98 | +150.50% | 1 | Apr 17, 2026 | |
| LBRX LB Pharmaceuticals | Maintains: Buy | $35 → $40 | $31.81 | +25.75% | 3 | Mar 27, 2026 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $39 → $42 | $19.16 | +119.21% | 2 | Mar 26, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $73 → $77 | $72.23 | +6.60% | 7 | Feb 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $25 → $24 | $22.30 | +7.62% | 7 | Feb 26, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $445 → $466 | $426.01 | +9.39% | 21 | Feb 13, 2026 | |
| QURE uniQure | Maintains: Buy | $50 → $40 | $17.90 | +123.46% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $128.04 | +46.83% | 11 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $18.04 | +116.19% | 5 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $495 → $508 | $308.51 | +64.66% | 16 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $30.64 | -8.62% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $3 | $2.22 | +35.14% | 3 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $73 → $61 | $53.81 | +13.37% | 11 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $144 → $202 | $180.67 | +11.81% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $1.60 | +650.00% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $85.20 | +10.33% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $39.21 | -18.39% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $19.60 | +63.31% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $8.89 | +23.73% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $2.35 | +70.21% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $24.27 | -58.80% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $27.05 | +121.81% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $33.73 | +6.73% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $35.40 | -1.13% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $13.00 | +123.08% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.63 | +255.56% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.57 | +2,000.47% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.52 | +971.43% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $6.94 | +822.19% | 1 | Feb 21, 2018 |
Definium Therapeutics
Apr 17, 2026
Initiates: Buy
Price Target: $30
Current: $20.98
Upside: +42.99%
Immunic
Apr 17, 2026
Initiates: Buy
Price Target: $25
Current: $9.98
Upside: +150.50%
LB Pharmaceuticals
Mar 27, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $31.81
Upside: +25.75%
KalVista Pharmaceuticals
Mar 26, 2026
Maintains: Buy
Price Target: $39 → $42
Current: $19.16
Upside: +119.21%
Ionis Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $73 → $77
Current: $72.23
Upside: +6.60%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $25 → $24
Current: $22.30
Upside: +7.62%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Hold
Price Target: $445 → $466
Current: $426.01
Upside: +9.39%
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $17.90
Upside: +123.46%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $128.04
Upside: +46.83%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $18.04
Upside: +116.19%
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $308.51
Upside: +64.66%
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $30.64
Upside: -8.62%
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $2.22
Upside: +35.14%
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $53.81
Upside: +13.37%
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $180.67
Upside: +11.81%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $1.60
Upside: +650.00%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $85.20
Upside: +10.33%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $39.21
Upside: -18.39%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $19.60
Upside: +63.31%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $8.89
Upside: +23.73%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $2.35
Upside: +70.21%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $24.27
Upside: -58.80%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $27.05
Upside: +121.81%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $33.73
Upside: +6.73%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $35.40
Upside: -1.13%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $13.00
Upside: +123.08%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $5.63
Upside: +255.56%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $0.57
Upside: +2,000.47%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.52
Upside: +971.43%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $6.94
Upside: +822.19%